Table 5.
Effectiveness according to the validated algorithm
| All (n=1,090) |
SC (n=785) |
IV (n=305) |
P-value IV versus SC |
ETN (n=440) |
ADA (n=345) |
P-value ETN versus ADA |
IFX (n=201) |
P-value ETN versus IFX |
ABA (n=104) |
P-value ETN versus ABA |
|
|---|---|---|---|---|---|---|---|---|---|---|---|
| Effectiveness, % patients | 32.2 | 35.9 | 22.6 | <0.001 | 36.4 | 35.4 | 0.77 | 21.9 | <0.001 | 24.0 | 0.02 |
| Reasons for deeming therapy not effective, % patients | |||||||||||
| Low adherence | 51.4 | 50.2 | 54.4 | 0.21 | 50.5 | 49.9 | 0.87 | 49.8 | 0.87 | 63.5 | 0.02 |
| Increased biologic dose | 10.1 | 3.2 | 27.9 | <0.001 | 0.5 | 6.7 | <0.001 | 38.8 | <0.001 | 6.7 | <0.001 |
| Biologic switch | 18.4 | 18.7 | 17.7 | 0.70 | 19.1 | 18.3 | 0.77 | 18.9 | 0.96 | 15.4 | 0.38 |
| New DMARD | 15.4 | 16.4 | 12.8 | 0.13 | 15.2 | 18.0 | 0.30 | 12.4 | 0.35 | 13.5 | 0.65 |
| Increase in glucocorticoid dose | 11.7 | 12.1 | 10.5 | 0.46 | 13.0 | 11.0 | 0.41 | 10.0 | 0.28 | 11.5 | 0.70 |
| Multiple joint injections | 7.8 | 6.2 | 11.8 | 0.002 | 6.4 | 6.1 | 0.87 | 9.5 | 0.16 | 16.4 | <0.001 |
Note: Values are presented as percent of patients or P-value.
Abbreviations: ABA, abatacept; ADA, adalimumab; DMARD, disease-modifying antirheumatic drug; ETN, etanercept; IFX, infliximab; IV, intravenous; SC, subcutaneous.